Table 2. Clinical and Psychological Characteristics of the RA Patients (n=204).
| Total (n=204) | Non-adherent (n=136) | Adherent (n=68) | p value | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Disease duration (yr) | 6.8 (2.5–12.0) | 6.0 (2.5–12.0) | 8.0 (2.1–13.0) | 0.413 |
| RA duration (≤5 yr) | 56 (27.5) | 43 (31.6) | 13 (19.1) | 0.370 |
| RA duration (>6 yr, ≤10 yr) | 53 (26) | 37 (27.2) | 16 (23.5) | 0.693 |
| RA duration (>10 yr, ≤20 yr) | 53 (26) | 33 (24.35) | 20 (29.4) | 0.535 |
| RA duration (>20 yr) | 11 (5.4) | 5 (3.7) | 6 (8.8) | 0.185 |
| Early RA (≤1 yr) | 31 (15.25) | 18 (13.2) | 13 (19.1) | 0.370 |
| Adverse events, yes | 41 (20.1) | 27 (19.9) | 14 (20.6) | >0.999 |
| Admission due to RA flare, yes | 33 (16.2) | 19 (14.0) | 14 (20.6) | 0.313 |
| Disease activity | ||||
| DAS-28 (ESR) | 3.8±1.3 | 3.8±1.2 | 3.9±1.5 | 0.464 |
| DAS-28 (CRP) | 3.1 (2.1–3.9) | 3.1 (2.1 – 4.0) | 2.9 (2.2 – 3.9) | 0.931 |
| Tender joint count | 2.0 (0.0–5.0) | 2.0 (0.0–5.0) | 2.0 (0.0–4.0) | 0.574 |
| Swollen joint count | 0.0 (0.0–1.0) | 0.0 (0.0–1.5) | 1.0 (0.0–1.0) | 0.329 |
| PGA | 3.0 (2.0–5.0) | 3.0 (2.0–4.0) | 3.0 (2.0–5.0) | 0.109 |
| VAS | 5.0 [3.0–6.0] | 4.5 [3.0–5.0] | 5.0 [3.0–6.0] | 0.196 |
| ESR (mm/hr) | 28.0 (15.5–49.0) | 27.5 (14.0–49.0) | 28.0 (17.0–46.0) | 0.988 |
| CRP (mg/L) | 2.6 (0.9–7.7) | 2.3 (0.8–7.2) | 3.0 (1.5 -10.7) | 0.254 |
| CDAI | 11.0 (6.0–16.2) | 10.0 (5.0–16.2) | 11.0 (7.5–16.5) | 0.761 |
| SDAI | 11.3 (6.2–17.7) | 11.3 (6.0–17.7) | 11.4 (7.8–18.3) | 0.690 |
| Low disease activity (DAS 28<3.2) | 94 (46.1) | 65 (47.8) | 29 (42.6) | 0.585 |
| Laboratory data | ||||
| White blood cell (109 cells/L) | 6.545 (5.795–7.910) | 6.455 (5.795–7.700) | 6.710 (5.795–8.320) | 0.299 |
| Hemoglobin (g/dL) | 13.0±1.3 | 13.1±1.3 | 12.9±1.2 | 0.206 |
| Platelet (109/L) | 270.4±62.8 | 266.6±56.0 | 278.4±74.4 | 0.245 |
| eGFR (mL/min/1.73 m2) | 92.0 (79.0–102.5) | 93.0 (81.0–102.0) | 89.5 (77.0–105.0) | 0.457 |
| RF positivity | 183 (91.0) | 124 (92.5) | 59 (88.1) | 0.432 |
| ACPA positivity | 128 (82.6) | 84 (80.8) | 44 (86.3) | 0.453 |
| Psychological characters | ||||
| PHQ-9 score | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 4.0 (2.0–9.5) | 0.683 |
| Depression (PHQ-9≥10) | 38 (18.6) | 21 (15.4) | 17 (25.0) | 0.144 |
| GAD-7 score | 2.0 (0.0–4.0) | 2.0 (1.0–4.0) | 1.0 (0.0–3.5) | 0.553 |
| Anxiety (GAD-7≥10) | 20 (9.8) | 12 (8.8) | 8 (11.8) | 0.677 |
| BC-CCI score | 5.0 (2.0–7.0) | 5.0 (3.0–8.0) | 5.0 (2.0–7.0) | 0.273 |
| HRQoL and functional disability | ||||
| EQ-5D-5L index value | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.174 |
| EQ-5D VAS, 0–100 | 70.0 (50.0–80.0) | 70.0 (50.0–80.0) | 70.0 (50.0–80.0) | 0.798 |
| HAQ score | 0.4 (0.0–0.9) | 0.4 (0.0–0.9) | 0.5 (0.1–1.1) | 0.121 |
| Personality traits | ||||
| Extroversion score | 3.0 (2.5–3.5) | 3.0 (2.5–3.5) | 3.0 (2.5–3.8) | 0.913 |
| Agreeableness score | 4.0 (3.5–4.5) | 4.0 (3.5–4.2) | 4.0 (3.5–4.5) | 0.416 |
| Conscientiousness score | 4.0 (3.5–4.5) | 4.0 (3.5–4.5) | 4.0 (3.5–4.5) | 0.067 |
| Neuroticism score | 2.5 (2.0–3.5) | 2.5 (2.0–3.5) | 2.8 (2.0–3.0) | 0.646 |
| Openness to experience score | 3.0 (2.5–3.5) | 3.0 (2.5–3.5) | 3.0 (2.5–3.5) | 0.302 |
RA, Rheumatoid arthriits; DAS-28, Disease Activity Score using 28 joints; ESR, Erythrocyte Sediment Rate; CRP, C-reactive protein; PGA, Physician Global Assessment; VAS, Visual Analog Scale; CDAI, Clinical Disease Activity Index; SDAI, Simplified Disease Activity Index; eGFR, Estimated Glomerular Filtration Rate; RF, eheumatoid factor; ACPA, anti-citrullinated protein antibody; PHQ-9, Patient Health Questionnaire-9; GAD-7, Generalized Anxiety Disorder-7; BC-CCI, The British Columbia-Cognitive Complaints Inventory; HRQoL, health-related Quality of Life; EQ-5D, EuroQoL-5 dimension questionnaire; HAQ, Health Assessment Questionnaire.
Data are presented as number (%), mean±SD, or median (IQR).